Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Chief Operating Officer | April 26, 2023 | April 28, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulcrum Therapeutics, Inc.
Report date April 26, 2023 · Filed April 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.58 · Expires 2033-04-25 | Direct | 115,000 |
Reported balance
After 2023-04-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-04-26 · Grant · Acquired 115,000 · Balance 115,000 F1: These stock options were granted to the reporting person under the Fulcrum 2019 Stock Incentive Plan (the "Plan") as part of an executive retention program and will vest 25% on the first anniversary of the grant date. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years, such that the options will be vested in full on the four-year anniversary of the grant date, and subject to the reporting person's continuing to be an "Eligible Participant" (as defined in the Plan) on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These stock options were granted to the reporting person under the Fulcrum 2019 Stock Incentive Plan (the "Plan") as part of an executive retention program and will vest 25% on the first anniversary of the grant date. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years, such that the options will be vested in full on the four-year anniversary of the grant date, and subject to the reporting person's continuing to be an "Eligible Participant" (as defined in the Plan) on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 26, 2023 Filed Apr 28, 2023 20:17 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 115,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0000950170-23-015832 · ownership.xml · derivative · entry 1 Hayes Melvin H. III · CIK 0001937148 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2033-04-25 F1 · derivative.exercise_date: These stock options were granted to the reporting person under the Fulcrum 2019 Stock Incentive Plan (the "Plan") as part of an executive retention program and will vest 25% on the first anniversary of the grant date. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years, such that the options will be vested in full on the four-year anniversary of the grant date, and subject to the reporting person's continuing to be an "Eligible Participant" (as defined in the Plan) on each such vesting date. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 21:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 135,000 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0000899243-23-004743 · doc4.xml · derivative · entry 1 Hayes Melvin H. III · CIK 0001937148 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2033-02-08 F1 · derivative.exercise_date: This option was granted on February 9, 2023 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2023, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 137,000 | $0.00 Strike: $7.40 | $0.00 |
DisclosureSEC source: 0000899243-22-028370 · doc4.xml · derivative · entry 1 Hayes Melvin H. III · CIK 0001937148 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,000 Underlying: Common Stock · 137,000 shares Expires 2032-08-08 F1 · derivative.exercise_date: This option was granted on August 9, 2022 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of August 9, 2022. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.